AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03457454 — intervention group
Intervention type: OTHER
Intervention: Colonoscopy Provider/Staff Participants Interviews
Description: -Approximately a 30 minute interview
Study NCT02475486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VistaO2
Description: ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
Study NCT03006354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nHFOV
Description: Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
Study NCT03006354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
Study NCT02981446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117
Description: DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
Study NCT02981446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Description: Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
Study NCT00583570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary education
Description: dietary education
Study NCT00339170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Based Cognitive Enhancement Training Program
Description: Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
Study NCT00339170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work Therapy Program
Description: Participants in the work therapy program will attend two non-cognitive discussion groups per week.
Study NCT00339170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Work Therapy Program
Description: Participants in the work therapy program will attend two non-cognitive discussion groups per week.
Study NCT05057286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical crown lengthening surgery
Description: * Clinical dental crown lengthening surgery protocol: a clinical crown lengthening surgery was performed.~* Post-operation protocol Patients were all prescribed antibiotics , anti-inflammation, analgesic, and an antiseptic mouthwash. Patients were instructed for oral hygiene and recalls.~* Botulinum Toxin A injection One hundred units (U) of botulinum toxin A (BTX-A) were diluted with 2.5ml of sterile saline solution without shaking. 1 mm syringe with a 30-gauge needle was used to get 0.25ml BTX-A for four-point injection, or 0.6ml in case injection of 6 points. Cold compress was applied extraoral 5 mins at injection site before injection.~After local anesthesia, the doctor administered slowly 2,5 U of diluted BTX-A at each point until white cellulite appeared.~Patients were recalled two weeks (T2), and two months (T3) after injection.
Study NCT04758182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy
Description: Device: HIRO 3.0 device high peak power (3kW), a wavelength of 1064 nm
Study NCT04758182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy
Description: Device: Chattanooga intellect mobile ultrasound device frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100%
Study NCT04556058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril tert-Butylamine tablets （ Produced by Haisco）
Description: The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
Study NCT04556058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril tert-Butylamine tablets（ACERTIL®）
Description: The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
Study NCT02257216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vayarin®
Description: Medical Food
Study NCT02257216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Cellulose
Study NCT02257216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose
Study NCT02211352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng Capsules
Description: Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Study NCT02211352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
Study NCT02810899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
Study NCT02810899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
Study NCT04575480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Lithotripsy for renal stone.
Description: The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with \<2 sessions will be excluded from the analysis
Study NCT03471871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
Study NCT03471871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
Study NCT03471871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 25 mg
Description: HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
Study NCT03471871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
Study NCT03471871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
Study NCT05777473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household Visits
Description: Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The community health worker will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male community health workers will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
Study NCT05777473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Groups
Description: In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week. The husband groups will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
Study NCT05777473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adopt-a-Friend
Description: The Adopt a Friend approach aims to promote the dissemination and discussion of new information and ideas among peers who are not directly involved in program activities. This involves asking each participant to choose a friend with whom she will share what she learns in home visits and her reflections. Adolescent girls will support each other in seeking sexual and reproductive health information or services if needed.
Study NCT02488889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Study NCT02488889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill (for varenicline)
Study NCT02488889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Study NCT02488889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo beverage (for alcohol)
Study NCT03576703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with and without SSB ingestion
Description: Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control
Study NCT04326647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: We used kinesiotaping in gastrocnemius and lumbar back
Study NCT04326647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises about balance and gait
Study NCT03017274 — intervention group
Intervention type: OTHER
Intervention: Abdominal ultrasound examination
Description: All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
Study NCT04478656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV121
Description: BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
Study NCT04478656 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BBV121
Description: BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
Study NCT02869776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Behavioral questionnaires
Study NCT02869776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid finger stick
Description: HIV and HCV testing through rapid finger stick
Study NCT02869776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: HIV and HCV testing through venipuncture
Study NCT00906360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally or by percutaneous gastrostomy tube
Study NCT00906360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00906360 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy
Study NCT00906360 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT01390181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cozaar
Description: Angiotensin II Receptor Blocker
Study NCT03658746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)
Description: Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
Study NCT03658746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one proton pump inhibitor, colloidal bismuth pectin
Description: All patients need these two drugs.
Study NCT03658746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one proton pump inhibitor, colloidal bismuth pectin
Description: All patients need these two drugs.
Study NCT03658746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)
Description: Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
Study NCT02513420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perineal muscle training
Description: It is a combination of perineal massage and Kegel exercises.
Study NCT04184440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclocarya paliurus extract
Description: The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .
Study NCT04184440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cyclocarya paliurus compounds
Description: The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .
Study NCT04184440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
Study NCT00893126 — intervention group
Intervention type: PROCEDURE
Intervention: CCTA Scan (Coronary CT Angiogram)
Description: CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
Study NCT02332109 — intervention group
Intervention type: DEVICE
Intervention: ODM 5
Description: ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
Study NCT03270904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moleculight i:X™ fluorescence imaging
Description: Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
Study NCT00646061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buscopan
Study NCT03656978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dynamic
Description: Use the according methods in dynamic arm descriptions.
Study NCT03656978 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular-triangle
Description: Use the according methods in regular-triangle arm descriptions.
Study NCT01969318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo /Metformin
Description: Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
Study NCT01969318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086(50 mg q.d.)/Metformin
Description: patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
Study NCT01969318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086 (100 mg q.d.)/Metformin
Description: patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
Study NCT01179451 — intervention group
Intervention type: DEVICE
Intervention: echocardiogram
Description: echocardiogram
Study NCT00355056 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.
Study NCT00355056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER PFO Occluder
Description: Patients in this arm will receive the AMPLATZER PFO Occluder device
Study NCT03184168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]lorlatinib
Description: Extemporaneously compounded oral solution of \[14C\]lorlatinib (approximately 100 mg/100 µCi)
Study NCT02222623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
Study NCT02222623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH
Description: NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
Study NCT00361296 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: K562/GM-CSF cell vaccine
Study NCT00826111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
Study NCT00391586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient
Study NCT00391586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
Study NCT01499355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB023
Study NCT01499355 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01499355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: titrated to a target daily dose of 2 g (1 g twice daily)
Study NCT00826111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.